Autologous Mesothelin-specific TCR-T Cell Therapy (Lonza Walkersville)

N/A

Report date: 2025/04/22 20:00:06

Base Information

Drug NameAutologous Mesothelin-specific TCR-T Cell Therapy (Lonza Walkersville)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionAnti-Mesothelin
TargetsMesothelin
Therapy Area/IndicationsPancreatic NeoplasmsCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFred Hutchinson Cancer Research Center
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsCarcinoma, Pancreatic Ductal

Other Information

ATC CodeN/A
Related LinksN/A